Table 1 Baseline participant characteristics and antiretroviral therapy (ART) history (n = 101)
Characteristic (N = 101) | n (%) |
|---|---|
Median Age (years)(Q1; Q3) | 15 (11;19) |
Education | Â |
 No education | 2(2.0) |
 Primary school | 33(32.7) |
 Secondary school | 66(65.3) |
Parental status | Â |
 Both parents alive | 20(19.8) |
 Maternal orphan | 17(16.8) |
 Paternal orphan | 20(19.8) |
 Double orphan | 44(43.6) |
Sexually active | Â |
 Yes | 5(5.0) |
ART history | Â |
 Current ART (Yes) | 91(90.1) |
 Not on ART | 10(9.9)* |
Duration of treatment (months)* | Â |
 < 6 | 1(1.1) |
 6 - <24 | 13(14.3) |
 24 - <60 | 34(37.3) |
 > 60 | 41(45.1) |
 Unknown | 2(2.2) |
Self-reported adherence to ART (> 96%)* |  |
 > 95% | 58(63.7) |
 ≤ 95% | 13(14.3) |
 Defaulter | 8(8.8) |
 Unknown | 12(13.2) |
The regimen of anti-retroviral drugs (N = 91) * |  |
 1st line (nevirapine-based antiretroviral therapy) | 77(84.6) |
 2nd line (Lopinavir/ritonavir-based antiretroviral therapy) | 13(14.3) |
 Unknown | 1(1.1) |
Immunological stage CD4 + T lymphocyte count (cell/mm3) * |  |
 Not significant immunosuppression  > 500 | 49(48.5) |
 Mild immunosuppression  350–499 | 23(22.8) |
 Advanced immunosuppression  200–349 | 14(13.9) |
 Severe immunosuppression  < 200 | 15(14.8) |
Average CD4 + count (Q1;Q3) | 497(19;2160) |